Harnessing tumor necrosis factor alpha to achieve effective cancer immunotherapy

Artículo

Autoría

MERCOGLIANO, MARIA FLORENCIA ; Bruni, Sofia ; Mauro, Florencia Luciana ; Elizalde, Patricia Virginia ; SCHILLACI, ROXANA

Fecha

2021

Editorial y Lugar de Edición

MDPI AG

Revista

Cancers, vol. 13 (pp. 1-33) - ISSN 2072-6694
MDPI AG

ISSN

2072-6694

Resumen Información suministrada por el agente en SIGEVA

Tumor necrosis factor alpha (TNF?) is a pleiotropic cytokine known to have contradictory roles in oncoimmunology. Indeed, TNF? has a central role in the onset of the immune response, inducing both activation and the effector function of macrophages, dendritic cells, natural killer (NK) cells, and B and T lymphocytes. Within the tumor microenvironment, however, TNF? is one of the main mediators of cancer-related inflammation. It is involved in the recruitment and differentiation of immune suppre... Tumor necrosis factor alpha (TNF?) is a pleiotropic cytokine known to have contradictory roles in oncoimmunology. Indeed, TNF? has a central role in the onset of the immune response, inducing both activation and the effector function of macrophages, dendritic cells, natural killer (NK) cells, and B and T lymphocytes. Within the tumor microenvironment, however, TNF? is one of the main mediators of cancer-related inflammation. It is involved in the recruitment and differentiation of immune suppressor cells, leading to evasion of tumor immune surveillance. These characteristics turn TNF? into an attractive target to overcome therapy resistance and tackle cancer. This review focuses on the diverse molecular mechanisms that place TNF? as a source of resistance to immunotherapy such as monoclonal antibodies against cancer cells or immune checkpoints and adoptive cell therapy. We also expose the benefits of TNF? blocking strategies in combination with immunotherapy to improve the antitumor effect and prevent or treat adverse immune-related effects.

Ver más Ver menos

Palabras Clave

IMMUNOTHERAPYIMMUNE CHECKPOINT INHIBITORCANCERTNF?ADOPTIVE CELL THERAPYMONOCLONAL ANTIBODY

Descargue o solicite el texto completo

http://hdl.handle.net/11336/137148